Faron Pharma gears up for pivotal year; bosses convinced by Traumakines potential

Faron Pharma gears up for “pivotal year”; bosses convinced by Traumakine’s potential

Traumakine disappointed in a late-stage ARDS study last year, but further analysis of the data showed that the drug was effective in certain patients, so another trial is in the works

More From BioPortfolio on "Faron Pharma gears up for “pivotal year”; bosses convinced by Traumakine’s potential"